Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 200 of 7998 results

  1. Technology appraisal guidance

    Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

  2. Our methods and processes (health technology evaluation manual)

    Our health technology evaluation manual covers: how we choose medicines and other health technologies to evaluate (topic selection) the steps and...

  3. Costs: charging for technology appraisals and highly specialised technologies

    Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.

  4. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  5. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.

  6. Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA968)

    NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA968

  7. Executive team meetings

    NICE executive team meeting minutes and agenda

  8. Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)

    NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA966

  9. Gender pay gap report

    The latest gender pay gap data from NICE

  10. British National Formulary (BNF)

    The BNF aims to provide prescribers, pharmacists, and other healthcare professionals with sound up-to-date information about the use of medicines. The

  11. NICE Listens

    NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social...

  12. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee. This is called the highly specialised

  13. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis. It aims to raise awareness of the symptoms of endometriosis, and to provide clear advice on what action to take when women and people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  14. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (IPG785)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

  15. Medtech innovation briefings

    Please note, from April 2023 NICE will no longer produce or maintain Medtech Innovation Briefings (MIBs) on behalf of NHS England. MIBs were...

  16. Quality standards advisory committee

    The quality standards advisory committees (QSAC) are independent committees that help to develop our quality standards . Come to a meeting Committee

  17. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  18. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  19. NICE recommended personalised immunotherapy to treat blood cancer in children and young adults to be made routinely available on the NHS

    Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.

  20. NICE launches second consultation on genetic testing to guide treatment after a stroke

    People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.

  21. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

  22. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  23. Committee D members

    Find out more about NICE technology appraisals advisory committee D members

  24. Executive team

    Biographies of the NICE executive team and minutes of their meetings

  25. Technology appraisal methods and processes used before 2022

    We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.

  26. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  27. Share your views and experiences of NICE

    We want to better understand views and experiences of NICE, from our audiences.

  28. Technology appraisal submission templates and supporting documents

    On this page, you'll find all the templates and supporting documents you need to make a technology appraisals submission. These templates have been...

  29. Modular updates for our technology appraisal guidance

    On this page, you'll find all our modular updates relating to our technology appraisal guidance. October 2023 NICE response to consultation on the...

  30. Technology appraisal position statements

    On this page, you'll find a list of all our position statements relating to our technology appraisal guidance. Biosimilar technologies: NICE position

  31. Using NICE guidance in social work

    A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.

  32. Overview: how we develop technology appraisal guidance

    1. Provisional appraisal topics chosen The NICE topic selection programme produces a list of provisional appraisal topics. 2. Stakeholders identified

  33. NICE guidance

    We use the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms. From this page, you can find

  34. Kurin Lock for blood culture collection (MTG77)

    Evidence-based recommendations on Kurin Lock for blood culture collection.

  35. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.

  36. GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  37. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  38. Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)

    NICE is unable to make a recommendation on sebelipase alfa (Kanuma) for treating lysosomal lipase deficiency that is not Wolman disease in adults. The Wolman disease population was evaluated separately in NICE highly specialised technology guidance on sebelipase alfa (HST30). The cost effectiveness of the remaining non-Wolman population has not been demonstrated at this stage.

    Sections for TA961

  39. Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)

    NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.

    Sections for TA965

  40. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

  41. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals

  42. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  43. Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)

    NICE is unable to make a recommendation on satralizumab (Enspryng) for preventing relapses in neuromyelitis optica spectrum disorders in adults

    Sections for TA960

  44. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

  45. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence

  46. UK licensing and technology appraisals

    What we do NICE has a key role in the evaluation of and access to new and innovative medicines and treatments for the health system, playing an...

  47. Medical technologies advisory committee

    Information, meeting dates and minutes of the medical technologies advisory committee

  48. Desflurane for maintenance of anaesthesia (ES41)

    Summary of the evidence on desflurane for maintenance of anaesthesia

  49. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people....

  50. Dementia: anti-psychotic prescriptions (IND12)

    This indicator covers the proportion of people with dementia prescribed anti-psychotic medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG18